Qube Research & Technologies (QRT)
CLDX icon

Qube Research & Technologies (QRT)’s Celldex Therapeutics CLDX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.6M Buy
+451,268
New +$17.3M 0.01% 1212
2024
Q3 		– Sell
-125,506
Closed -$4.64M – 3407
2024
Q2 		$4.64M Sell
125,506
-80,658
-39% -$3.04M 0.01% 1291
2024
Q1 		$8.65M Buy
206,164
+161,196
+358% +$6.62M 0.01% 925
2023
Q4 		$1.78M Buy
44,968
+40,669
+946% +$1.2M ﹤0.01% 1581
2023
Q3 		$118K Sell
4,299
-64,548
-94% -$2.02M ﹤0.01% 2609
2023
Q2 		$2.34M Buy
68,847
+6,902
+11% +$233K 0.01% 987
2023
Q1 		$2.23M Buy
61,945
+28,271
+84% +$1.22M 0.01% 957
2022
Q4 		$1.5M Buy
33,674
+26,198
+350% +$935K 0.01% 1049
2022
Q3 		$210K Buy
+7,476
New +$229K ﹤0.01% 1759
2021
Q2 		– Sell
-64,913
Closed -$1.34M – 2320
2021
Q1 		$1.34M Sell
64,913
-106,405
-62% -$2.44M 0.02% 735
2020
Q4 		$3M Buy
171,318
+97,734
+133% +$1.76M 0.04% 464
2020
Q3 		$1.09M Buy
73,584
+37,250
+103% +$436K 0.02% 790
2020
Q2 		$472K Buy
+36,334
New +$161K 0.01% 1140

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CLDX Position: Q3 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Celldex Therapeutics (CLDX) in Q3 2026: 451,268 shares worth $14.6M. The stake represents 0.01% of the portfolio and ranks #1212 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in CLDX as recently as Q2 2024.

Qube Research & Technologies (QRT) first reported a position in CLDX in Q2 2020 and has held it in 13 quarters since. 166 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Qube Research & Technologies (QRT) held 451,268 shares of Celldex Therapeutics worth $14.6M as of Q3 2026.
  • Celldex Therapeutics was a new Qube Research & Technologies (QRT) position in Q3 2026.
  • Celldex Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q3 2026, its #1212 holding.
  • Qube Research & Technologies (QRT) first reported a position in Celldex Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • 166 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.